Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial
(2024)
Journal Article
Austin, D., Maier, R. H., Akhter, N., Sayari, M., Ogundimu, E., Maddox, J. M., Vahabi, S., Humphreys, A. C., Graham, J., Oxenham, H., Haney, S., Cresti, N., Verrill, M., Osborne, W., Wright, K. L., Goranova, R., Bailey, J. R., Kalakonda, N., Macheta, M., Kilner, M. F., …Plummer, C. (2024). Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial. Journal of the American College of Cardiology, 6(5), 684-696. https://doi.org/10.1016/j.jaccao.2024.07.010
Background
Cardiotoxicity is a concern for cancer survivors undergoing anthracycline chemotherapy. Enalapril has been explored for its potential to mitigate cardiotoxicity in cancer patients. The dose-dependent cardiotoxicity effec...
Read More about Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial.